Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: The role of the DFG motif in the design of epidermal growth factor receptor inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 3889-3903

  Peng, Yi Hui ^a   Shiao, Hui Yi ^a   Tu, Chih Hsiang ^a,b   Liu, Pang Min ^a   Hsu, John Tsu An ^a   Amancha, Prashanth Kumar ^a   Wu, Jian Sung ^a   Coumar, Mohane Selvaraj ^c   Chen, Chun Hwa ^a   Wang, Sing Yi ^a   Lin, Wen Hsing ^a   Sun, Hsu Yi ^a   Chao, Yu Sheng ^a   Lyu, Ping Chiang ^b   Hsieh, Hsing Pang ^a   Wu, Su Ying ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c PONDICHERRY UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINO ACID DERIVATIVE; ASPARTIC ACID; ASPARTYLPHENYLALANYLGLYCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GLYCINE DERIVATIVE; N,N, DIMETHYLAMINO; PHENYL GROUP; PROTEIN KINASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; IC 50; NONHUMAN; PROTEIN FOLDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RING OPENING; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MUTATION; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878095831     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400072p     Document Type: Article

References (71)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934
2. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
3. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nature Rev. Cancer 2009, 9, 28-39
4. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases Cell 2002, 109, 275-282
5. Nagar, B. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571) J. Nutr. 2007, 137, 1518S-1523S
6. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog EMBO J. 1997, 16, 5572-5581
7. Hubbard, S. R.; Wei, L.; Ellis, L.; Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor Nature 1994, 372, 746-754
8. Sicheri, F.; Moarefi, I.; Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck Nature 1997, 385, 602-609
9. Schlessinger, J. Common and distinct elements in cellular signaling via EGF and FGF receptors Science 2004, 306, 1506-1507
10. Hynes, N. E.; MacDonald, G. ErbB receptors and signaling pathways in cancer Curr. Opin. Cell Biol. 2009, 21, 177-184
11. Ernst, E. Mistletoe for cancer? Eur. J. Cancer 2001, 37, 9-11
12. Klapper, L. N.; Kirschbaum, M. H.; Sela, M.; Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Adv. Cancer Res. 2000, 77, 25-79
13. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 2000, 19, 3159-3167
14. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 2002, 277, 46265-46272
15. Kim, S.; Prichard, C. N.; Younes, M. N.; Yazici, Y. D.; Jasser, S. A.; Bekele, B. N.; Myers, J. N. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Clin. Cancer Res. 2006, 12, 600-607
16. Baselga, J.; Averbuch, S. D. ZD1839 ('Iressa') as an anticancer agent Drugs 2000, 60, 33-40
17. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007, 11, 217-227
18. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol. Cancer Ther. 2001, 1, 85-94
19. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 2004, 64, 6652-6659
20. Yokoi, K.; Thaker, P. H.; Yazici, S.; Rebhun, R. R.; Nam, D. H.; He, J.; Kim, S. J.; Abbruzzese, J. L.; Hamilton, S. R.; Fidler, I. J. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model Cancer Res. 2005, 65, 3716-3725
21. Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling Clin. Cancer Res. 2006, 12, 6186-6193
22. Aertgeerts, K.; Skene, R.; Yano, J.; Sang, B. C.; Zou, H.; Snell, G.; Jennings, A.; Iwamoto, K.; Habuka, N.; Hirokawa, A.; Ishikawa, T.; Tanaka, T.; Miki, H.; Ohta, Y.; Sogabe, S. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein J. Biol. Chem. 2011, 286, 18756-18765
23. Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiyama, K. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2- d ]pyrimidine scaffold J. Med. Chem. 2011, 54, 8030-8050
24. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res. 2004, 64, 3958-3965
25. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U S A. 2008, 105, 2070-2075
26. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074
27. Eskens, F. A.; Mom, C. H.; Planting, A. S.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br. J. Cancer 2008, 98, 80-85
28. Solca, F.; Dahl, G.; Zoephel, A.; Bader, G.; Sanderson, M.; Klein, C.; Kraemer, O.; Himmelsbach, F.; Haaksma, E.; Adolf, G. R. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker J. Pharmacol. Exp. Ther. 2012, 343, 342-350
29. Kalous, O.; Conklin, D.; Desai, A. J.; O'Brien, N. A.; Ginther, C.; Anderson, L.; Cohen, D. J.; Britten, C. D.; Taylor, I.; Christensen, J. G.; Slamon, D. J.; Finn, R. S. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib Mol. Cancer Ther. 2012, 11, 1978-1987
30. Ramalingam, S. S.; Blackhall, F.; Krzakowski, M.; Barrios, C. H.; Park, K.; Bover, I.; Seog Heo, D.; Rosell, R.; Talbot, D. C.; Frank, R.; Letrent, S. P.; Ruiz-Garcia, A.; Taylor, I.; Liang, J. Q.; Campbell, A. K.; O'Connell, J.; Boyer, M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 2012, 30, 3337-3344
31. Chang, S. C.; Chang, C. Y.; Chang, S. J.; Yuan, M. K.; Lai, Y. C.; Liu, Y. C.; Chen, C. Y.; Kuo, L. C.; Yu, C. J. Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer Clin. Lung Cancer 2012, 14, 55-61
32. Widakowich, C.; de Castro, G., Jr.; de Azambuja, E.; Dinh, P.; Awada, A. Review: side effects of approved molecular targeted therapies in solid cancers Oncologist 2007, 12, 1443-1455
33. Castellino, S.; O'Mara, M.; Koch, K.; Borts, D. J.; Bowers, G. D.; MacLauchlin, C. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity Drug Metab. Dispos. 2012, 40, 139-150
34. Lovly, C. M.; Horn, L. Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC Curr. Treat. Options Oncol. 2012, 13, 516-526
35. Yamamoto, N.; Honma, M.; Suzuki, H. Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders Mol. Pharmacol. 2011, 80, 466-475
36. Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y. F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3- carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J. Med. Chem. 2005, 48, 1107-1131
37. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 2004, 64, 6652-6659
38. Coumar, M. S.; Chu, C. Y.; Lin, C. W.; Shiao, H. Y.; Ho, Y. L.; Reddy, R.; Lin, W. H.; Chen, C. H.; Peng, Y. H.; Leou, J. S.; Lien, T. W.; Huang, C. T.; Fang, M. Y.; Wu, S. H.; Wu, J. S.; Chittimalla, S. K.; Song, J. S.; Hsu, J. T.; Wu, S. Y.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification J. Med. Chem. 2010, 53, 4980-4988
39. Huang, S. F.; Liu, H. P.; Li, L. H.; Ku, Y. C.; Fu, Y. N.; Tsai, H. Y.; Chen, Y. T.; Lin, Y. F.; Chang, W. C.; Kuo, H. P.; Wu, Y. C.; Chen, Y. R.; Tsai, S. F. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin. Cancer Res. 2004, 10, 8195-8203
40. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 2002, 62, 4236-4243
41. Lawrence, H. R.; Martin, M. P.; Luo, Y.; Pireddu, R.; Yang, H.; Gevariya, H.; Ozcan, S.; Zhu, J. Y.; Kendig, R.; Rodriguez, M.; Elias, R.; Cheng, J. Q.; Sebti, S. M.; Schonbrunn, E.; Lawrence, N. J. Development of o -chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors J. Med. Chem. 2012, 55, 7392-7416
42. Kuglstatter, A.; Ghate, M.; Tsing, S.; Villasenor, A. G.; Shaw, D.; Barnett, J. W.; Browner, M. F. X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 5217-5220
43. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nature Struct. Biol. 2002, 9, 268-272
44. Alevy, Y. G.; Patel, A. C.; Romero, A. G.; Patel, D. A.; Tucker, J.; Roswit, W. T.; Miller, C. A.; Heier, R. F.; Byers, D. E.; Brett, T. J.; Holtzman, M. J. IL-13-induced airway mucus production is attenuated by MAPK13 inhibition J. Clin. Invest. 2012, 122, 4555-4568
45. Seeliger, M. A.; Ranjitkar, P.; Kasap, C.; Shan, Y.; Shaw, D. E.; Shah, N. P.; Kuriyan, J.; Maly, D. J. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Res. 2009, 69, 2384-2392
46. Seeliger, M. A.; Nagar, B.; Frank, F.; Cao, X.; Henderson, M. N.; Kuriyan, J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty Structure 2007, 15, 299-311
47. Hodous, B. L.; Geuns-Meyer, S. D.; Hughes, P. E.; Albrecht, B. K.; Bellon, S.; Caenepeel, S.; Cee, V. J.; Chaffee, S. C.; Emery, M.; Fretland, J.; Gallant, P.; Gu, Y.; Johnson, R. E.; Kim, J. L.; Long, A. M.; Morrison, M.; Olivieri, P. R.; Patel, V. F.; Polverino, A.; Rose, P.; Wang, L.; Zhao, H. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2886-2889
48. Hodous, B. L.; Geuns-Meyer, S. D.; Hughes, P. E.; Albrecht, B. K.; Bellon, S.; Bready, J.; Caenepeel, S.; Cee, V. J.; Chaffee, S. C.; Coxon, A.; Emery, M.; Fretland, J.; Gallant, P.; Gu, Y.; Hoffman, D.; Johnson, R. E.; Kendall, R.; Kim, J. L.; Long, A. M.; Morrison, M.; Olivieri, P. R.; Patel, V. F.; Polverino, A.; Rose, P.; Tempest, P.; Wang, L.; Whittington, D. A.; Zhao, H. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor J. Med. Chem. 2007, 50, 611-626
49. Hughes, S.; Elustondo, F.; Di Fonzo, A.; Leroux, F. G.; Wong, A. C.; Snijders, A. P.; Matthews, S. J.; Cherepanov, P. Crystal structure of human CDC7 kinase in complex with its activator DBF4 Nature Struct. Mol. Biol. 2012, 19, 1101-1107
50. Echalier, A.; Cot, E.; Camasses, A.; Hodimont, E.; Hoh, F.; Jay, P.; Sheinerman, F.; Krasinska, L.; Fisher, D. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity Chem. Biol. 2012, 19, 1028-1040
51. Hole, A. J.; Baumli, S.; Shao, H.; Shi, S.; Huang, S.; Pepper, C.; Fischer, P. M.; Wang, S.; Endicott, J. A.; Noble, M. E. Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5- carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity J. Med. Chem. 2013, 56, 660-670
52. Lafleur, K.; Dong, J.; Huang, D.; Caflisch, A.; Nevado, C. Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography J. Med. Chem. 2013, 56, 84-96
53. Tsuhako, A. L.; Brown, D. S.; Koltun, E. S.; Aay, N.; Arcalas, A.; Chan, V.; Du, H.; Engst, S.; Franzini, M.; Galan, A.; Huang, P.; Johnston, S.; Kane, B.; Kim, M. H.; Laird, A. D.; Lin, R.; Mock, L.; Ngan, I.; Pack, M.; Stott, G.; Stout, T. J.; Yu, P.; Zaharia, C.; Zhang, W.; Zhou, P.; Nuss, J. M.; Kearney, P. C.; Xu, W. The design, synthesis, and biological evaluation of PIM kinase inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 3732-3738
54. Staben, S. T.; Siu, M.; Goldsmith, R.; Olivero, A. G.; Do, S.; Burdick, D. J.; Heffron, T. P.; Dotson, J.; Sutherlin, D. P.; Zhu, B. Y.; Tsui, V.; Le, H.; Lee, L.; Lesnick, J.; Lewis, C.; Murray, J. M.; Nonomiya, J.; Pang, J.; Prior, W. W.; Salphati, L.; Rouge, L.; Sampath, D.; Sideris, S.; Wiesmann, C.; Wu, P. Structure-based design of thienobenzoxepin inhibitors of PI3-kinase Bioorg. Med. Chem. Lett. 2011, 21, 4054-4058
55. Fugel, W.; Oberholzer, A. E.; Gschloessl, B.; Dzikowski, R.; Pressburger, N.; Preu, L.; Pearl, L. H.; Baratte, B.; Ratin, M.; Okun, I.; Doerig, C.; Kruggel, S.; Lemcke, T.; Meijer, L.; Kunick, C. 3,6-Diamino-4-(2-halophenyl)-2- benzoylthieno[2,3- b ]pyridine-5-carbonitriles are selective inhibitors of Plasmodium falciparum glycogen synthase kinase-3 J. Med. Chem. 2013, 56, 264-275
56. Bhattacharya, S. K.; Aspnes, G. E.; Bagley, S. W.; Boehm, M.; Brosius, A. D.; Buckbinder, L.; Chang, J. S.; Dibrino, J.; Eng, H.; Frederick, K. S.; Griffith, D. A.; Griffor, M. C.; Guimaraes, C. R.; Guzman-Perez, A.; Han, S.; Kalgutkar, A. S.; Klug-McLeod, J.; Garcia-Irizarry, C.; Li, J.; Lippa, B.; Price, D. A.; Southers, J. A.; Walker, D. P.; Wei, L.; Xiao, J.; Zawistoski, M. P.; Zhao, X. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 7523-7529
57. Forsyth, T.; Kearney, P. C.; Kim, B. G.; Johnson, H. W.; Aay, N.; Arcalas, A.; Brown, D. S.; Chan, V.; Chen, J.; Du, H.; Epshteyn, S.; Galan, A. A.; Huynh, T. P.; Ibrahim, M. A.; Kane, B.; Koltun, E. S.; Mann, G.; Meyr, L. E.; Lee, M. S.; Lewis, G. L.; Noguchi, R. T.; Pack, M.; Ridgway, B. H.; Shi, X.; Takeuchi, C. S.; Zu, P.; Leahy, J. W.; Nuss, J. M.; Aoyama, R.; Engst, S.; Gendreau, S. B.; Kassees, R.; Li, J.; Lin, S. H.; Martini, J. F.; Stout, T.; Tong, P.; Woolfrey, J.; Zhang, W.; Yu, P. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 7653-7658
58. Wenglowsky, S.; Moreno, D.; Laird, E. R.; Gloor, S. L.; Ren, L.; Risom, T.; Rudolph, J.; Sturgis, H. L.; Voegtli, W. C. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 6237-6241
59. Zapf, C. W.; Gerstenberger, B. S.; Xing, L.; Limburg, D. C.; Anderson, D. R.; Caspers, N.; Han, S.; Aulabaugh, A.; Kurumbail, R.; Shakya, S.; Li, X.; Spaulding, V.; Czerwinski, R. M.; Seth, N.; Medley, Q. G. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay J. Med. Chem. 2012, 55, 10047-10063
60. Ranjitkar, P.; Perera, B. G.; Swaney, D. L.; Hari, S. B.; Larson, E. T.; Krishnamurty, R.; Merritt, E. A.; Villen, J.; Maly, D. J. Affinity-based probes based on type II kinase inhibitors J. Am. Chem. Soc. 2012, 134, 19017-19025
61. Aronov, A. M.; Baker, C.; Bemis, G. W.; Cao, J.; Chen, G.; Ford, P. J.; Germann, U. A.; Green, J.; Hale, M. R.; Jacobs, M.; Janetka, J. W.; Maltais, F.; Martinez-Botella, G.; Namchuk, M. N.; Straub, J.; Tang, Q.; Xie, X. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors J. Med. Chem. 2007, 50, 1280-1287
62. Williams, N. K.; Bamert, R. S.; Patel, O.; Wang, C.; Walden, P. M.; Wilks, A. F.; Fantino, E.; Rossjohn, J.; Lucet, I. S. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 2009, 387, 219-232
63. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics 2010, 26, 198-204
64. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature 1995, 376, 313-320
65. Lin, W. H.; Song, J. S.; Chang, T. Y.; Chang, C. Y.; Fu, Y. N.; Yeh, C. L.; Wu, S. H.; Huang, Y. W.; Fang, M. Y.; Lien, T. W.; Hsieh, H. P.; Chao, Y. S.; Huang, S. F.; Tsai, S. F.; Wang, L. M.; Hsu, J. T.; Chen, Y. R. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors Anal. Biochem. 2008, 377, 89-94
66. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025
67. Bailey, S. The CCP4 suite: programs for protein crystallography Acta.Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763
68. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
69. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110-119
70. Joosten, R. P.; Salzemann, J.; Bloch, V.; Stockinger, H.; Berglund, A.-C.; Blanchet, C.; Bongcam-Rudloff, E.; Combet, C.; Da Costa, A. L.; Deleage, G.; Diarena, M.; Fabbretti, R.; Fettahi, G.; Flegel, V.; Gisel, A.; Kasam, V.; Kervinen, T.; Korpelainen, E.; Mattila, K.; Pagni, M.; Reichstadt, M.; Breton, V.; Tickle, I. J.; Vriend, G. PDB-REDO: automated re-refinement of X-ray structure models in the PDB J. Appl. Crystallogr. 2009, 42, 376-384
71. Chen, V. B.; Arendall, W. B., III; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 12-21